BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/14/2025 12:55:52 PM | Browse: 109 | Download: 377
 |
Received |
|
2024-11-18 09:02 |
|
Peer-Review Started |
|
2024-11-18 09:02 |
|
First Decision by Editorial Office Director |
|
2025-03-08 05:32 |
|
Return for Revision |
|
2025-03-08 05:38 |
|
Revised |
|
2025-03-19 09:37 |
|
Publication Fee Transferred |
|
2025-03-20 04:18 |
|
Second Decision by Editor |
|
2025-05-27 02:39 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-05-27 07:38 |
|
Articles in Press |
|
2025-05-27 07:38 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-06-27 07:12 |
|
Publish the Manuscript Online |
|
2025-07-14 12:55 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Importance of landscape exploration and progress in molecular therapies and precision medicine for pancreatic ductal adenocarcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Maher Hendi, Bin Zhang, Yi-Ping Mou and Xiu-Jun Cai |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xiu-Jun Cai, Chief Physician, FACS, FRCS, MD, PhD, President, Professor, Department of General Surgery, Zhejiang University School of Medicine, Sir Run Run Shaw Hospital, No. 3 Qingchun Road, Hangzhou 310016, Zhejiang Province, China. srrs_cxj@zju.edu.cn |
| Key Words |
Pancreatic ductal adenocarcinoma; Molecular subtypes; Transcriptomic; Microenvironment; Precision medicine; Therapeutic targets; Immunotherapy |
| Core Tip |
Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer death globally and is projected to be the second leading cause later. Kirsten rat sarcoma oncogene is a critical target for treatment regime evaluation in pancreatic ductal adenocarcinoma and proof of principle approaches have validated targeting in Kirsten rat sarcoma oncogene G12C. FOLFIRINOX and nab-paclitaxel gemcitabine are gold standard therapeutic in patients. The combinations were shown a survival benefit over previously standard gemcitabine monotherapy. Therapies targeting as well as immuno-therapies hold promise for the future but are currently not standard of care. |
| Publish Date |
2025-07-14 12:55 |
| Citation |
Hendi M, Zhang B, Mou YP, Cai XJ. Importance of landscape exploration and progress in molecular therapies and precision medicine for pancreatic ductal adenocarcinoma. World J Gastrointest Oncol 2025; 17(7): 103337 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i7/103337.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i7.103337 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
